Study participants were randomly assigned tezepelumab subcutaneous injection or placebo. The co-primary endpoints were change from baseline in total nasal polyp size (measured by endoscopic total ...
GlobalData on MSN6d
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trialA Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...
For people with allergies, ongoing exposure to triggers may create a cycle of inflammation that contributes to polyp ...
AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps. Chronic rhinosinusitis is a disorder characterised by ...
Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Amgen and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial ...
for patients with severe chronic rhinosinusitis with nasal polyps, demonstrating significant reductions in polyp size and nasal congestion compared to placebo. The trial involved symptomatic ...
AstraZeneca (NASDAQ:AZN) and Amgen (NASDAQ:AMGN) have announced positive outcomes from the Phase III WAYPOINT trial of TEZSPIRE (tezepelumab) for patients with severe chronic rhinosinusitis with nasal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback